Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step ...

Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...

PE: What is the reaction to DTC pharma advertising? Donaldson: Consumers will slowly but surely have increased distrust in ...

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk ...

Osuka America Pharmaceutical’s president and CEO Tarek Rabah spoke with Pharmaceutical Executive about the company’s mission and how its investing in psychedelics and other major areas. Pharmaceutical ...

On Feb. 25, Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) announced raids on two locations in Lincolnshire and Nottinghamshire, seizing almost 2,000 doses of illegal weight-loss ...

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

Novo Nordisk partners with Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, while GSK agrees to acquire 35Pharma Inc. to expand its pulmonary hypertension ...

David Graziano, head of retail network at GoodRx, says the FDA’s crackdown on non-approved or “copycat” GLP-1 drugs could shift demand toward FDA-approved therapies while increasing the importance of ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

David Graziano, head of retail network at GoodRx, says the FDA’s crackdown on non-approved or “copycat” GLP-1 drugs could shift demand toward FDA-approved therapies while increasing the importance of ...